Drug Profile


Alternative Names: CT-053; CT-053-PTSA; Ningetinib tosylate

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HEC Pharm
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c met inhibitors; RON protein inhibitors; Signal transduction pathway modulators; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Non-small cell lung cancer
  • Discontinued Glioblastoma

Most Recent Events

  • 25 Apr 2017 Sunshine Lake Pharma plans a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) in China (PO) (NCT03125876)
  • 25 Aug 2016 Phase-I clinical trials in Acute myeloid leukaemia in China (PO) (HEC Pharm pipeline, August 2016)
  • 25 Aug 2016 Phase-I clinical trials in Non-small cell lung cancer in China (PO) (HEC Pharm pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top